Willow Biosciences Inc.

TSX:WLLW Stock Report

Market Cap: CA$13.7m

Willow Biosciences Management

Management criteria checks 2/4

Willow Biosciences' CEO is Chris Savile, appointed in Mar 2023, has a tenure of 1.67 years. directly owns 0.94% of the company’s shares, worth CA$129.42K. The average tenure of the management team and the board of directors is 5.6 years and 1.8 years respectively.

Key information

Chris Savile

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure1.7yrs
CEO ownership0.9%
Management average tenure5.6yrs
Board average tenure1.8yrs

Recent management updates

Recent updates

Is Willow Biosciences (TSE:WLLW) In A Good Position To Deliver On Growth Plans?

Apr 11
Is Willow Biosciences (TSE:WLLW) In A Good Position To Deliver On Growth Plans?

We Think Willow Biosciences (TSE:WLLW) Needs To Drive Business Growth Carefully

Dec 20
We Think Willow Biosciences (TSE:WLLW) Needs To Drive Business Growth Carefully

We Think Willow Biosciences (TSE:WLLW) Can Afford To Drive Business Growth

Sep 02
We Think Willow Biosciences (TSE:WLLW) Can Afford To Drive Business Growth

We Think Willow Biosciences (TSE:WLLW) Can Easily Afford To Drive Business Growth

May 20
We Think Willow Biosciences (TSE:WLLW) Can Easily Afford To Drive Business Growth

Calculating The Fair Value Of Willow Biosciences Inc. (TSE:WLLW)

Jan 19
Calculating The Fair Value Of Willow Biosciences Inc. (TSE:WLLW)

CEO Compensation Analysis

How has Chris Savile's remuneration changed compared to Willow Biosciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-CA$8m

Jun 30 2024n/an/a

-CA$9m

Mar 31 2024n/an/a

-CA$11m

Dec 31 2023n/an/a

-CA$13m

Sep 30 2023n/an/a

-CA$15m

Jun 30 2023n/an/a

-CA$17m

Mar 31 2023n/an/a

-CA$17m

Dec 31 2022CA$584kCA$358k

-CA$15m

Sep 30 2022n/an/a

-CA$15m

Jun 30 2022n/an/a

-CA$7m

Mar 31 2022n/an/a

CA$2m

Dec 31 2021CA$749kCA$297k

-CA$6m

Sep 30 2021n/an/a

-CA$16m

Jun 30 2021n/an/a

-CA$27m

Mar 31 2021n/an/a

-CA$44m

Dec 31 2020CA$447kCA$297k

-CA$34m

Sep 30 2020n/an/a

-CA$22m

Jun 30 2020n/an/a

-CA$16m

Mar 31 2020n/an/a

-CA$45m

Dec 31 2019CA$789kCA$209k

-CA$45m

Compensation vs Market: Insufficient data to establish whether Chris's total compensation is reasonable compared to companies of similar size in the Canadian market.

Compensation vs Earnings: Chris's compensation has been consistent with company performance over the past year.

CEO

Chris Savile

1.7yrs

Tenure

CA$584,324

Compensation

Dr. Chris Savile serves as President and Chief Executive Officer Willow Biosciences Inc. since March 28, 2023. He served as its Chief Operations Officer since April 7, 2020 until 2023. Dr. Savile served as...

Leadership Team

NamePositionTenureCompensationOwnership
Travis Doupe
Chief Financial Officer5.6yrsCA$376.55k1.07%
CA$ 146.9k
Chris Savile
President1.7yrsCA$584.32k0.94%
CA$ 129.4k
Sanjib Gill
Corporate Secretary5.6yrsno datano data

5.6yrs

Average Tenure

Experienced Management: WLLW's management team is seasoned and experienced (5.6 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Chris Savile
President1.7yrsCA$584.32k0.94%
CA$ 129.4k
Donald Archibald
Independent Director5.6yrsCA$95.25k1.3%
CA$ 177.5k
James Lalonde
Independent Chairman1.8yrsCA$68.14k0.27%
CA$ 36.7k
Albert Foreman
Director5.6yrsCA$91.50k0.049%
CA$ 6.7k
Raffi Asadorian
Independent Director1.5yrsCA$48.30k0.0046%
CA$ 632.9

1.8yrs

Average Tenure

59yo

Average Age

Experienced Board: WLLW's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.